Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease Inhibitor

Grazoprevir (GZR) plus elbasvir is an approved treatment for chronic infection with hepatitis C virus (HCV) genotype 1 or 4. HCV infection complications include liver cirrhosis, end-stage liver disease, and hepatocellular carcinoma. The objective of this study was to evaluate the pharmacokinetics an...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Caro, Luzelena, Wenning, Larissa, Guo, Zifang, Fraser, Iain P., Fandozzi, Christine, Talaty, Jennifer, Panebianco, Deborah, Ho, Maureen, Uemura, Naoto, Reitmann, Christina, Angus, Peter, Gane, Edward, Marbury, Thomas, Smith, William B., Iwamoto, Marian, Butterton, Joan R., Yeh, Wendy W.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2017
Matèries:
Antiviral Agents
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5700330/
https://ncbi.nlm.nih.gov/pubmed/28947470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00813-17
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars